Cancer Treatment with Novocure

Harris and Novocure, a commercial stage private oncology company, entered into a long-term supply agreement in August, 2011 to supply Novocure with the piezoelectric ceramic components used to manufacture the disposable electrodes for Optune™, an FDA approved device indicated for the treatment of adult patients with recurrent glioblastoma brain tumors.

We provide piezoelectric ceramic components to Novocure for their Optune device that battles Glioblastoma (GBM) tumors with electric fields.

Optune is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The Optune device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.

Learn more about Novocure's tumor treating field technology.